Reneuron plc, of Guildford, UK, provided an update on progress with the PISCES trial of its ReN001 stem cell therapy for disabled stroke patients. Interim data from the first nine patients treated in the PISCES study are being presented by the clinical team from Glasgow's Southern General Hospital at the 22nd European Stroke Conference, taking place in London this week.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter